RT Journal Article
SR Electronic
T1 Apolipoprotein E Genotypes in Patients with Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 707
OP 711
VO 36
IS 2
A1 YENCILEK, FARUK
A1 YILMAZ, SEDA GULEC
A1 YILDIRIM, ASIF
A1 GORMUS, UZAY
A1 ALTINKILIC, EMRE MURAT
A1 DALAN, ALTAY BURAK
A1 BASTUG, YAVUZ
A1 TURKMEN, SELDA
A1 TURKAN, SADI
A1 ISBIR, TURGAY
YR 2016
UL http://ar.iiarjournals.org/content/36/2/707.abstract
AB Background: Apolipoprotein E (ApoE) is a potential inhibitor of cell proliferation, immune regulation and modulation of cell growth and differentiation; it also has a substantial role in antioxidant activity. ApoE has a potential role in prostate cancer progression. Materials and Methods: ApoE genotyping was performed using real-time polymerase chain reaction (RT-PCR) for blood samples from a group of patients with prostate cancer (n=68) and a control group (n=78). Results: The frequency of the E3/E3 genotype was significantly higher in patients compared to controls (p=0.004). E3/E3 genotype carriers were 3.6-fold more likely to be patients than controls (odds ratio=3.67, 95% confidence interval=1.451-9.155; p=0.004). Additionally, the patients with E3/E3 genotype had significantly higher Gleason score (p=0.017), and more patients with this genotype had a Gleason score higher than 7 (p=0.007). Individuals carrying the E4 allele were significantly more common in the control group (p=0.006). The frequency of the E3/E4 genotype was found to be significantly higher in controls compared to patients (p=0.007), and patients were significantly less likely to have this genotype than controls (odds ratio=0.89, 95% confidence interval=0.833-0.967, p=0.007). Individuals carrying the E2/E3 genotype had a significantly lower Gleason score (p=0.049)–all of the patients with this genotype had a Gleason score lower than 7 (p=0.024). Conclusion: E3/E3 genotype may be a potential risk factor for prostate cancer and high Gleason scoring. The E4 allele maybe a risk-reducing factor for prostate cancer.